Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) (Q28280453)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) |
scientific article |
Statements
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) (English)
Kim A Papp
1 reference
Craig L Leonardi
Newman Yeilding
Cynthia Guzzo
Yuhua Wang
Shu Li
Lisa T Dooley
Kenneth B Gordon
PHOENIX 1 study investigators
Identifiers
2 references
2 references